1 in 5 adults in the U.S. experience mental illness each year. This #MentalIllnessAwarenessWeek, we’re committed to redefining #psychiatry with #PrecisionMedicine. At Alto, we believe in tailored treatments for every individual, providing access through decentralized #ClinicalTrials, and supporting better mental health for all. Learn more from NAMI about how you can get involved: https://lnkd.in/erd3HWWM
关于我们
Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. Alto's Precision Psychiatry Platform? measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.
- 网站
-
https://www.altoneuroscience.com
Alto Neuroscience的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Los Altos，CA
- 类型
- 上市公司
- 创立
- 2019
地点
-
主要
获取路线
US，CA，Los Altos，94022
Alto Neuroscience员工
动态
-
Meet Sarah Long, Ph.D., a Senior R&D Engineer here at Alto. When Sarah isn’t in the Mountain View office project planning, coding, analyzing data, product testing, or designing, she can likely be found cooking, painting, reading, playing pickleball, or mountain biking. ?? #MeetTheTeam
-
-
?? Our CEO, Amit Etkin, will participate in a fireside chat at the Cowen Inc. 4th Annual Novel Mechanisms in Neuropsychiatry Summit. conference. Access the webcast here: https://bit.ly/47cFfII
-
-
Our CEO, Amit Etkin will join Nikolaos Mellios, M.D., Ph.D. and Chia-Yen Chen, Sc.D. in a panel discussion of precision therapeutics at the 4th Annual Conference on Precision Psychiatry, presented by Massachusetts General Hospital. We look forward to discussing #PrecisionPsychiatry with physicians and fellow industry leaders. Learn more about the conference here: https://bit.ly/47eR6pC
-
-
Our team will be attending the 37th ECNP Congress! We're eager to connect with leading experts in #psychiatry and #neuropsychiatry to collaborate and share insights that drive innovation in #Psychiatric care. More info here: https://bit.ly/4dV9DK7 #ECNP2024 European College of Neuropsychopharmacology (ECNP)
-
-
In case you missed it, our leadership team and Dr. Gerard Sanacora shared the latest on #PrecisionPsychiatry at our recent Investor Day. The event focused on our upcoming ALTO-100 Phase 2b data readout in #MajorDepressiveDisorder. Watch the recording here: https://bit.ly/3MWzfdz
-
At the Cantor Fitzgerald Annual Healthcare Conference, our CEO Amit Etkin will share corporate highlights and information on our #PrecisionPsychiatry approach. #CantorHCC More here: https://bit.ly/3ThaJr8
-
-
Next week, our CEO Amit Etkin will participate in a panel discussion at the Foundation for the National Institutes of Health's #TeamScienceDay2024. The panel will focus on decoding depression and predicting outcomes in #MentalHealth. More info here: https://bit.ly/4gdF18g #BridgesToBreakthroughs
-
At this year's BioCentury Inc. Grand Rounds, our CMO Adam Savitz, M.D., Ph.D., will join other #neuropsychiatry experts in a panel discussion focused on identifying new targets to redefine treatments. Learn more about the panel here: https://bit.ly/3MCeNhZ
-
-
On #WorldSuicidePreventionDay, we stand united in raising awareness and supporting #MentalHealth for all. It's crucial to remember that help is always available. We at Alto are dedicated to redefining #psychiatry to match people with the right treatment quickly. Together, we have the potential to make a difference. #StartTheConversation